delafloxacin meglumine

delafloxacin meglumine (BAXDELA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

BAXDELA is a marketed brand name for delafloxacin meglumine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

delafloxacin meglumine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.